Navigation Links
Sangui Partnership Enters a New Phase:

Second Wound Ambulance Established in Monterrey

MONTERREY, Mexico, and WITTEN, Germany, December 4 /PRNewswire-FirstCall/ -- Sangui Latino America and Sangui BioTech GmbH executives jointly opened another wound management ambulance in the center of Monterrey, Mexico, on the occasion of a three day working visit. Sangui BioTech GmbH Managing Director Hubertus Schmelz and Sangui Marketing Representative Renate Pentzien discussed the next steps of the successful cooperation of the two companies with the Mexican partners. An enlarged series of cosmetics presented by Renate Pentzien on this occasion met considerable interest.

State health authorities support approval and practical use of wound management products

Submitted were letters of the State Ministry of Health of the Mexican state of Tamaulipas. In those letters the health authorities underscore their support of both, the further wound management projects as well as the planned preclinical and clinical tests aiming at the approval of Sangui's blood additive. Starting early in 2008, clinical studies will be carried out at the General Hospital of Ciudad Victoria, Tamaulipas' capital, using Sangui's wound management products (Scabremove for wound debridement, the Hemospray wound spray and the Chitoskin wound pad) on another 30 patients suffering from chronic wounds. In charge of the studies will be specialist doctors at this hospital in cooperation with Sangui medical staff. It is being anticipated that the studies will be accomplished in the course of the first half of 2008.

According to additional information provided by Sangui Latino America, a health authority approval of the Sangui products as medical products will be available shortly after the successful accomplishment of this study. Moreover, Sangui Latino America indicated that the State of Tamaulipas intends to make comprehensive practical use of Sangui's products in hospitals and medical institutions under its responsibility.

Both companies appreciated this official commitment as the most important result of their cooperation so far. It underlines the succes of the therapeutic work carried out in the private ambulances, which completely yielded the expected healing results. According to the Mexican partners, a medical products approval by the Tamaulipas State Ministry will immediately put Sangui in the position to service not only the Mexican but also the entire Latin American market.

Mexico counts approximately 17 million diabetes II patients, the care and therapy of whom consumes more than 30% of the Mexican health budget - at a still increasing percentage. Other reasons for the occurrence of chronic wounds include ulcus cruris or amputations, all of which are eligible for treatments with Sangui products. Clinical data obtained in Mexico will be beneficial also for the EU approval process, which continues to be on schedule.

Definite planning starts for blood additive project

The Tamaulipas State Ministry has additionally declared its comprehensive support for the blood additive project including in particular the preclinical and clinical studies. Sangui Latino America and Sangui BioTech GmbH, therefore, have started definite planning aimed at the fastest and most efficient ways to carry out this key project. The respective planning how to produce the test substance needed for the preclinical testing has already been completed. Currently, the favourite option is to establish the production facility in the existing clean rooms of Sangui BioTech in Witten, Germany. The test design describing the toxicological as well as pharmacological tests of the preclinical phase will be written in close cooperation with the authorities in Ciudad Victoria. Starting immediately, test designs for possible clinical studies will be elaborated in mutual understanding of all parties involved. The target is to identify and weigh different possible indications including in particular heart attack and lung shock. It is the common understanding of the partners to look at a project start in the course of the first half of 2008.

The two companies in Germany and Mexico which are not affiliated legally have established a trustful partnership which now becomes increasingly closer.

Hubertus Schmelz underscores, therefore: "We are very satisfied with the course things in Mexico are now taking thanks to the energy of our partners. Their commitment, their willingness to invest and their determination are paramount examples for the industry. They allowed our wound management products to show in a large number of patients that they actually work the way we expected them to. Based on the test results obtained so far we expect that we will be able to accomplish the additional 30 patient study successfully and at short notice. The entailing official approval as medical products would give us access to important and large markets. And, we are particularly excited about the prospects for the blood additive - as this key venture of our company will enter definite planning and roll-out at last. We are more than grateful for our partners in Mexico. It is their strong commitment which makes all this fast progress happen."

The joint prospects are being confirmed by Sangui Latino America President Eduardo Mena: "In the past couple of months, we have been able to convince ourselves that Sangui's wound management products and concepts do keep what they promise. We are determined, therefore, to further extend our commitment and to take the necessary steps towards product approval in close accordance with the Tamaulipas authorities. Jointly also we shall proceed with the blood additive project, as we consider it a product which will eventually help treating severly ill patients and even save their lives. We are well aware of the financial requirements, but we are deeply convinced that this is an investment which will pay back."

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. ( SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49(160)741-27-17

Fax: +49(2302)915-191


SOURCE Sangui BioTech International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
3. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
4. Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM)
5. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
6. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
7. Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area
8. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
9. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
10. LifeNet Health and IMS Announce Partnership
11. Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management
Post Your Comments:
(Date:10/12/2017)... ... 12, 2017 , ... The Blavatnik Family Foundation and the ... of the 2017 Blavatnik Regional Awards for Young Scientists. Established in 2007, ... the New York Academy of Sciences to honor the excellence of outstanding postdoctoral ...
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
Breaking Biology Technology:
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
Breaking Biology News(10 mins):